{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:56:04Z","timestamp":1777949764159,"version":"3.51.4"},"reference-count":32,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022217","name":"Flinders Foundation","doi-asserted-by":"crossref","award":["Tour de Cure Support Grant \/ AH03390"],"award-info":[{"award-number":["Tour de Cure Support Grant \/ AH03390"]}],"id":[{"id":"10.13039\/501100022217","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Doug Henderson Research Fund bequest"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,2,24]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This is a phase 1, open-label, single-centre, uncontrolled, dose-escalation study to evaluate the feasibility, tolerability and pharmacokinetic profiles of a single dose of liposomal curcumin, administered via an existing tunnelled indwelling pleural catheter (TIPC) directly to the tumour site in individuals with diagnoses of malignant pleural effusion. Primarily, we aim to determine a maximum tolerated dose of liposomal curcumin administered via this method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      We will use a 3+3 expanded cohort for predefined dose-escalation levels or until a predefined number of dose-limiting toxicities are reached. Participants will be administered a single dose of liposomal curcumin (LipoCurc, SignPath Pharma) via their existing TIPC as a sequential enrolling case series with the following dose cohorts: 100, 200 and 300 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Primary endpoints are determination of the maximum tolerated dose within the predetermined dose range, and determination of the feasibility of intrapleural administration of liposomal curcumin via an existing TIPC. Secondary endpoints include determination of the safety and tolerability of intrapleural administration of liposomal curcumin, median overall survival, effects on quality of life and on feelings of breathlessness, and the pharmacokinetics and concentrations of curcumin from the plasma and the pleural fluid. Important inclusion criteria include age \u226518 years, an existing TIPC, a pleural biopsy or pleural fluid cytology-proven diagnosis of malignant pleural effusion and for whom no antitumour therapy of proven benefit is available or has been previously declined, eastern cooperative group performance status &lt;2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol has been approved by the Southern Adelaide Local Health Network Human Research Ethics Committee (HREC) (approval number: HREC\/20\/SAC\/11). Study results will be published in peer-reviewed journals, and presented at conferences, in field of medical oncology and respiratory medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12620001216909.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Protocol version number<\/jats:title>\n                    <jats:p>V.1.0.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-047075","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T11:20:52Z","timestamp":1617016852000},"page":"e047075","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Study protocol of a phase 1 clinical trial establishing the safety of intrapleural administration of liposomal curcumin: curcumin as a palliative treatment for malignant pleural effusion (IPAL-MPE)"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-8984","authenticated-orcid":false,"given":"Ashleigh Jean","family":"Hocking","sequence":"first","affiliation":[{"name":"Anatomical Pathology, Flinders University, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0909-8978","authenticated-orcid":false,"given":"Alexandra L","family":"Farrall","sequence":"additional","affiliation":[{"name":"Anatomical Pathology, Flinders University, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Newhouse","sequence":"additional","affiliation":[{"name":"School of Medicine, Flinders University, Bedford Park, South Australia, Australia"},{"name":"Respiratory and Sleep Services, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sordillo","sequence":"additional","affiliation":[{"name":"Sign Path Pharma,Inc, Sandy, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Greco","sequence":"additional","affiliation":[{"name":"Respiratory and Sleep Services, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos Stelios","family":"Karapetis","sequence":"additional","affiliation":[{"name":"School of Medicine, Flinders University, Bedford Park, South Australia, Australia"},{"name":"Medical Oncology, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Dougherty","sequence":"additional","affiliation":[{"name":"Respiratory and Sleep Services, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Klebe","sequence":"additional","affiliation":[{"name":"Anatomical Pathology, Flinders University, Bedford Park, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"2025121219263754000_11.3.e047075.1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0019-2016"},{"key":"2025121219263754000_11.3.e047075.2","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-015-0025-z","article-title":"Important prognostic factors for survival in patients with malignant pleural effusion","volume":"15","author":"Zamboni","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2025121219263754000_11.3.e047075.3","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12496"},{"key":"2025121219263754000_11.3.e047075.4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205285"},{"key":"2025121219263754000_11.3.e047075.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5535"},{"key":"2025121219263754000_11.3.e047075.6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/ejcts\/ezy258","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions","volume":"55","author":"Bibby","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025121219263754000_11.3.e047075.7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. An official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121219263754000_11.3.e047075.8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209464"},{"key":"2025121219263754000_11.3.e047075.9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1064"},{"key":"2025121219263754000_11.3.e047075.10","doi-asserted-by":"publisher","DOI":"10.3390\/molecules20022728"},{"key":"2025121219263754000_11.3.e047075.11","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1124\/pr.110.004044","article-title":"The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer","volume":"66","author":"Heger","year":"2014","journal-title":"Pharmacol Rev"},{"key":"2025121219263754000_11.3.e047075.12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijpharm.2012.12.032","article-title":"Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis","volume":"443","author":"Liu","year":"2013","journal-title":"Int J Pharm"},{"key":"2025121219263754000_11.3.e047075.13","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.2147\/IJN.S132434","article-title":"Liposomal curcumin and its application in cancer","volume":"12","author":"Feng","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"2025121219263754000_11.3.e047075.14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00286"},{"key":"2025121219263754000_11.3.e047075.15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5414\/CP202076","article-title":"Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans","volume":"53","author":"Storka","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025121219263754000_11.3.e047075.16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00280-018-3654-0","article-title":"A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc\u2122) in patients with locally advanced or metastatic cancer","volume":"82","author":"Greil","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025121219263754000_11.3.e047075.17","first-page":"4359","article-title":"Tissue distribution of (Lipocurc\u2122) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in beagle dogs","volume":"32","author":"Matabudul","year":"2012","journal-title":"Anticancer Res"},{"key":"2025121219263754000_11.3.e047075.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.802"},{"key":"2025121219263754000_11.3.e047075.19","first-page":"373","article-title":"Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions","volume":"3","author":"Perez-Soler","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2025121219263754000_11.3.e047075.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026732"},{"key":"2025121219263754000_11.3.e047075.21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/0002-9378(89)90296-2","article-title":"A phase I\/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer","volume":"160","author":"Delgado","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"2025121219263754000_11.3.e047075.22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/IJN.S237536","article-title":"The safety and exploration of the pharmacokinetics of intrapleural liposomal curcumin","volume":"15","author":"Hocking","year":"2020","journal-title":"Int J Nanomedicine"},{"key":"2025121219263754000_11.3.e047075.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025121219263754000_11.3.e047075.24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025121219263754000_11.3.e047075.25","first-page":"2895","article-title":"Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions","volume":"21","author":"Cheng","year":"2001","journal-title":"Anticancer Res"},{"key":"2025121219263754000_11.3.e047075.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0744"},{"key":"2025121219263754000_11.3.e047075.27","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-10-0098"},{"key":"2025121219263754000_11.3.e047075.28","doi-asserted-by":"publisher","DOI":"10.1016\/0300-483X(80)90122-5"},{"key":"2025121219263754000_11.3.e047075.29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0773.1978.tb02240.x","article-title":"A study on the fate of curcumin in the rat","volume":"43","author":"Wahlstr\u00f6m","year":"1978","journal-title":"Acta Pharmacol Toxicol"},{"key":"2025121219263754000_11.3.e047075.30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp079"},{"key":"2025121219263754000_11.3.e047075.31","unstructured":"Common terminology criteria for adverse events (CTCAE) v5.0. published online on the National cancer Insitute website at, 2018. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"2025121219263754000_11.3.e047075.32","unstructured":"Australian code for the responsible conduct of research Camberra: National health and medical Research Council 2018."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-047075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:26:45Z","timestamp":1765596405000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-047075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/bmjopen-2020-047075"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-047075","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}